Exploring the Pharmacological Properties of Nicotine: Ulcerative Colitis and Schizophrenic Disorders Through a Scientific Lens
Chronic tobacco combustion remains a leading preventable cause of premature mortality worldwide, driving malignancies, chronic obstructive pulmonary disease (COPD), and atherothrombotic cardiovascular events. In clinical pharmacology, however, a strict distinction must be drawn between toxic tobacco smoke—which delivers over 7,000 combustion compounds including roughly 70 carcinogens—and the isolated pyridine alkaloid nicotine. Neuropharmacological and gastroenterological investigations have revealed that selective activation of nicotinic acetylcholine receptors (nAChRs) modulates the cholinergic anti-inflammatory pathway in ulcerative colitis and influences sensory gating in schizophrenia.